Navigation Links
MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Date:9/29/2010

ffers to buy any securities of MAP Pharmaceuticals and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the conduct and completion of clinical trials, and relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent o
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:4/17/2014)... estimated that as many as 10 million older Americans ... loneliness and isolation. , However, new research a ... older Americans for six years found that Internet ... depression by more than 30 percent. , "That,s a ... University professor of telecommunication, information studies and media who ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... ... Sufferers , ... March 30, 2010 -- Those with aching backs might want to look at their home ... color schemes and price range, but many don,t take time to consider products that can ...
... ... ... Tahitian Noni International (TNI) announced that their 2011 International Leadership Conference would ... of the most luxurious cruise ships in the world. The announcement was received with such ...
... ... improved longevity , ... YORK (PRWEB) March 30, 2010 -- CogniFit™, Inc., a leading maker of Brain Fitness ... longevity, author and speaker, is now an official spokesperson for CogniFit. Berg, who is ...
... ... For New Web Hosting Sign-ups , ... Vancouver, Canada (PRWEB) March 30, 2010 -- Canadian Web Hosting ( ... announced an increase of benefits for their popular affiliate program. The immediate increase from ...
... Boston University School of Medicine found that women with serum ... risk of developing gout than men. This study, the ... gout risk in women, also evaluated purported risk factors for ... and diuretic use to be among leading contributors for women. ...
... What makes some viral infections fatal and others much ... that a part of the variability can be attributed ... Professor Michael Katze, presenting at the Society for General ... modelling could be a powerful tool to allow treatments ...
Cached Medicine News:Health News:Proper Home Dcor May Assist in Alleviating Back Pain 2Health News:Proper Home Dcor May Assist in Alleviating Back Pain 3Health News:Caribbean Cruise Announced by Tahitian Noni International for 2011 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 2Health News:CogniFit and Longevity Expert Cooperate to Raise Awareness for the Benefits of Brain Fitness 3Health News:Canadian Web Hosting Increases Affiliate Incentive 2Health News:Obesity, hypertension, alcohol and diuretic use -- gout risk factors for women 2Health News:Personalizing medicine to prevent pandemics 2
... neurophysiological monitoring system has been designed ... the needs of the ever changing ... collection and analyzing data from multiple ... EMG, EEG and multiple patients at ...
... Inc. is the largest independently ... to ophthalmic surgical instrumentation. Katena ... 7,000 customers in the United ... network of distributors, to customers ...
... Studies have proven that the management of diabetes ... glucose levels is the most effective way to ... care aimed at maintaining or improving a diabetes ... and costly. , ,These have been the ...
... is intended for detecting trends and tracking ... 18 and older) and children/adolescents (aged 7 ... the use of the G2 Biographer with ... to supplement, not replace, conventional blood glucose ...
Medicine Products: